Go To TTD's Pre-Market Opening Breakout Watch Stock Lists for Monday, April 20
|
Go To TTD's Pre-Market Opening Breakout Watch Stock Lists for Monday, April 20 |
| Go to Video Show - "How to Make Money With Breakout Stocks" |
|
Go to Video Show - "How to Make Money With Breakout Stocks" |
|---|
Ticker Tape Digest presents its daily breakout and Short Selling report.
It contains Breakout Stocks and Stocks under Significant Accumulation. 
Data is from tape action for the day. These stocks are most suitable for aggressive investors seeking ideal entry points for leading stocks.
These stocks will do very well during bull markets and strong market rallies.
TTD also presents Stocks To Sell or Sell Short. These issues are suitable for aggressive investors willing to take short positions both as trades or for longer-term plays. These stocks
will do very well during bear markets or market corrections
TTD's multi-media updates include a slide-show that presents charts and analysis at midsession. Some times TTD presents feature analysis on stocks and the market. TTD uses Windows Media Files. (WMV).
TTD also presents a "Breakout Watch List" that is up dated daily. This list consists of key stocks in position to breakout. A close watch of this list can put you in the stock just as it breaks out.
TTD often suggests using stop buy orders to enter. It is very important to buy a breakout stock as close as possible to the break point. The idea is to get "elbow room" if the stock should follow through to the upside. This is very important in being successful in making big money with breakout stocks.
TTD also has special feature sections on Educational Tips on Investing.
To email Mr. Leo Fasciocco leo@tickertapedigest.com.For service, email Beverly Owen owen@tickertapedigest.com. TTD’s Tel: 1-480-926-1680.
Stocks Screened - 8,200
Bull's Strategy - No breakouts today. Market falls sharply on contracting volume. Bulls be patient and watchful of all long positions. Weekly indicators turn down. Earnings reports need to be watched.
(Put mouse on Dow chart to see Nasdaq chart)
Long Term Environment for bulls: Neutral
Market (Daily) - NYSE Bearish, Nasdaq Bearish
Market (Weekly) -NYSE Bearish, Nasdaq Bearish
Market (Monthly) NYSE Bullish, Nasdaq Bullish
(No breakouts today. TTD features a stock that recently broke out.)
| TTD's Quality Rating of Stock - MDRX - AVERAGE |
MDRX, based in Libertyville, Il., develops and markets clinical software and information solutions to physicians. Annual revenues: $313 million. MDRX is a rebounding stock in the medical sector that recently broke out from a four-month base. TTD did not find any breakouts today. So, we feature MDRX. Today, the stock rises slightly weathering the stormy selloff in the stock market. The stock has followed through on its breakout. TTD suggests a partial position. 
So far today, MDRX is up slightly. Volume is running at 1.7 million shares. Its average daily volume is 2.5 million shares.
The stock rose in the morning making a six-month high. It then drifted lower in the morning. It trended sideways in the afternoon.
TTD's clip of the tape highlights the big block trades of the past two sessions. One can see the price for the blocks rising from $11.20 to $11.75. A key trade was a big block of 50,000 shares crossing at $11.73. The tape action indicates good institutional buying interest.
The company's clinical solutions group provides electronic health records, document imaging, and e-prescribing tools. The medication services group provides medication fulfillment services.
TTD's performance chart shows that MDRX's stock has appreciated 105% the past six months. That compares with a 5% decline in the S&P 500 index. So, MDRX has been an exceptionally strong stock lately.
TTD's long-term chart shows MDRX stock with a powerful advance from $1.14 back in early 2003. The stock peaked at $18.71 in early 2007. It then went into a decline with the bear market. It has since made the turn up. TTD rates the stock only an "average breakout" because it has yet to make a new high. 
MDRX's daily chart shows the stock having formed a four-month, flat base bracketed between roughly 8 and 10. The stock broke out on March 25. It bobbed around the breakpoint and then turned higher. That is what draws TTD to the stock.
The stock's TTD momentum indicator (top of the chart) is solidly bullish.
The accumulation - distribution line (bottom of chart) is in a strong up trend and has broken out to the upside. That is good confirmation of the price breakout.
This fiscal year ending May 30, analysts predict a 20% increase in MDRX's net to 47 cents a share from 39 cents a year ago. The stock sells with a price-earnings ratio of 24, which is reasonable given the steady earnings growth.
Going out to fiscal 2010 ending in May, the Street projects an 18% gain in net to 55 cents a share.
The company is benefiting from increased services and products.
Net for the upcoming fiscal fourth quarter ending in May should increase 20% to 13 cents a share from 11 cents a year ago. The highest estimate on the Street is at 15 cents a share. TTD sees good chances for an upside surprise. The past two quarters, MDRX has topped the consensus estimate by 2 cents a share.
Strategy Opinion: MDRX's stock is slightly extended off its breakpoint. However, its ability to hold against the market decline is bullish. TTD suggests a partial stake with further buying to be done by averaging up. TTD is targeting the stock for a move to 14.50. A protective stop can be placed near 10. TTD rates MDRX a good intermediate-term play because of its good earnings outlook.
Sponsorship: Very Good. There are four five-star rated funds holding the stock. The second largest fund holder is 5-star rated Buffalo Small Cap Fund with a 1.3% stake. The largest buyer lately was 5-star rated Transamerica Small/Mid Cap Value Fund which purchased 845,000 shares. MDRX has 142 million shares outstanding. Funds hold 15.6 million shares.
Insider Activity: Bearish. Some heavy selling lately by Misys Holdings Inc. The selling took place around 9 in March. Currently, 18 analysts follow the stock, just 4 have a buy, the same as three months ago.
Stock Performance Chart for 6 months with Quarterly Earnings Markers.
|
TTD's Profile Rating Allscripts Misys Healthcare - (MDRX) |
| TTD Check List | Bullish | Bearish | Neutral |
| Near 52-week High | YES | ||
| Volume Expansion | YES | ||
| Tick Volume | YES | ||
| Price Trend - Daily | YES | ||
| Price Trend - Long Term | YES | ||
| Price Daily Spread | YES | ||
| Base Structure | YES | ||
| Base - A-D | YES | ||
| Earnings-Quarterly | YES | ||
| Earnings-Long Term | YES | ||
| Earnings Outlook | YES | ||
| Industry Group | YES | ||
| Prior Breakout Success | YES | ||
| Fund Sponsorship | YES | ||
| Total Score | 9 | 0 | 5 |
(The “breakout List” gives all stocks breaking out of a base of five weeks or more. These stocks have a good chance to trend higher. However, a stop should be used to avoid those that do not work. (Trading strategy: One should buy breakout stocks at breakpoint by using market order or stop buy.
Charts of Breakout Stocks
None
Ticker Tape Digest’s Daily List of “Stocks To Sell or Sell Short” ranks stocks well timed to be sold immediately based on daily trading. The list can be used as an alert to reduce current long-term positions.
Shorts from tape action so far today - 6
Stocks Screened - 8,200
Long-Term Environment for bears: Neutral
Bear Side - Small list of breakdown stocks today as stock market moves sharply lower. Bears be alert now and aggressive.
(Trading strategy: These stocks can be sold short, or if held should be sold. If a stock is sold short, a protective stop buy should be placed. Short plays work best when the stock market is in a down trend.)
AMGN, based near Los Angeles, is a biotech firm with expertise in renal disease and cancer supportive care products. Annual revenues: $15 billion. AMGN's stock fall sharply today undercutting key support. With just flat earnings expected this year, TTD sees potential for more on the downside for bears. So far today, AMGN is trading 6.9 million shares. Its average daily volume is 9 million shares.
AMGN's stock fell in the morning and trended lower until the early afternoon. It staged a minor rally in the afternoon.
TTD's clip of the tape highlights a big block of 50,954 shares crossing on a down tick to $46.56 from the prior trade at $46.62. The tape action indicates heavy institutional selling pressure.
AMGN's key drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases.
The company introduced its first cancer therapeutic, Vectibix, in 2006, and late-stage development efforts range from osteoporosis treatments to cancer antibodies.
This year, analysts forecast just a 1% rise in net to $4.53 a share from $4.48 a year ago. Net for the upcoming first quarter should be up just 3%.
TTD's daily chart shows AMGN's stock breaking sharply to the downside in February. The stock was able to mount just a minor lift after the selloff. Now, It is breaking below key support. The stock's accumulation - distribution line (bottom of chart) is in a sharp down trend indicating clear heavy selling pressure.
Strategy Opinion: AMGN is a big cap play in the drug sector. The technical breakdown today with upcoming weak earnings signals potential for more on the downside. TTD is targeting AMGN for a decline to 38 within the next few months, or sooner. A protective stop can be placed near 48.
TTD columnist Leo Fasciocco has covered the stock market for over 20 years. His articles appear in many publications. He is also a speaker at the Intershow conferences. He has been on television and radio. He is author of many educational articles about stock investing and the book “Guide To High-Performance Investing.”
For information to subscribe to the Ticker Tape Digest Services call: B. J. Owen at 1-480-926-1680. Distributed by Corona Publishing Enterprises. Ticker Tape Digest Inc. P.O. Box 2044 Chandler, Az. 85244-2044. TTD “Professional Report” is available on the World Wide Web: $100 per month. Password needed. “TTD Professional“ Faxed is $200 per month. The TTD Daily Report is $39.95. Credit cards accepted.
(The information contained has been prepared from data deemed reliable but there is no guarantee of complete accuracy. Ticker Tape Digest Inc. is not affiliated with any broker, dealer or investment advisor. Nothing in this publication constitutes an offer, recommendation or solicitation to buy or sell any securities. Further research is advised. This report is copyrighted and no redistribution is permitted with out permission. Some of the charts are from Telescan, Insight Trading, First Alert and other sources.)
